Clinical Trial Update: APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating APL-2 with pembrolizumab versus APL-2 with pembrolizumab plus bevacizumab versus bevacizumab alone for recurrent ovarian, fallopian tub…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• APL-2 (pegylated C3 inhibitor)
• Avastin (bevacizumab)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Status: RECRUITING